CXCL12与CXCR7是多发性骨髓瘤中逆转细胞黏附介导耐药的相关靶点
骨髓介导的细胞黏附耐药(CAM-DR)是多发性骨髓瘤(MM)进展和存活的基础。研究假设新型抗骨髓瘤药物的细胞毒效应可被骨髓基质细胞(BMSCs)削弱,并通过加入CXCL12拮抗剂NOX-A12或CXCR4抑制剂普乐沙福而恢复。体外共培养显示普乐沙福或NOX-A12可干扰MM向骨髓的趋化,使MM细胞对伏立诺他、泊马度胺、硼替佐米和卡非佐米重新敏感;多中心I/II期研究中NOX-A12联合硼替佐米-地塞米松显示了可行性。
要点
- CXCR4、CD49d和CD44被验证为MM细胞骨髓黏附的关键介质,CXCR7在活动性MM中高表达。
- 普乐沙福或NOX-A12可功能性干扰MM向骨髓的趋化,逆转BMSCs对伏立诺他、泊马度胺、硼替佐米和卡非佐米的保护效应。
- 多中心I/II期研究显示NOX-A12联合硼替佐米-地塞米松具有可行性,可作为拮抗骨髓瘤CAM-DR的活性添加药物。
核心结论
- CXCL12及其二受体CXCR4和CXCR7是逆转多发性骨髓瘤细胞黏附介导耐药的相关靶点,NOX-A12联合硼替佐米-地塞米松在多中心I/II期研究中显示可行性。
研究设计与样本
- 体外共培养研究评估抗骨髓瘤药物单用、与骨髓基质细胞共培养及联合普乐沙福或NOX-A12的效应。
- 多中心I/II期研究测试NOX-A12联合硼替佐米-地塞米松。
主要发现
- CXCR4、CD49d(ITGA4)和CD44被验证为MM细胞骨髓黏附的关键介质。
- CXCR7作为基质细胞衍生因子-1(CXCL12)的第二受体,在活动性MM中高表达。
- 共培养证实普乐沙福或NOX-A12(后者抑制CXCR4和CXCR7)可功能性干扰MM向骨髓的趋化。
- 联合普乐沙福或NOX-A12使MM细胞对伏立诺他、泊马度胺及蛋白酶体抑制剂硼替佐米和卡非佐米重新敏感。
临床怎么用
- 多中心I/II期研究显示NOX-A12联合硼替佐米-地塞米松具有可行性,支持NOX-A12作为拮抗骨髓瘤CAM-DR的活性添加药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell adhesion-mediated drug resistance (CAM-DR) by the bone marrow (BM) is fundamental to multiple myeloma (MM) propagation and survival. Targeting BM protection to increase the efficacy of current anti-myeloma treatment has not been extensively pursued. To extend the understanding of CAM-DR, we hypothesized that the cytotoxic effects of novel anti-myeloma agents may be abrogated by the presence of BM stroma cells (BMSCs) and restored by addition of the CXCL12 antagonist NOX-A12 or the CXCR4 inhibitor plerixafor. Following this hypothesis, we evaluated different anti-myeloma agents alone, with BMSCs and when combined with plerixafor or NOX-A12. We verified CXCR4, CD49d (also termed ITGA4) and CD44 as essential mediators of BM adhesion on MM cells. Additionally, we show that CXCR7, the second receptor of stromal-derived-factor-1 (CXCL12), is highly expressed in active MM. Co-culture proved that co-treatment with plerixafor or NOX-A12, the latter inhibiting CXCR4 and CXCR7, functionally interfered with MM chemotaxis to the BM. This led to the resensitization of MM cells to the anti-myeloma agents vorinostat and pomalidomide and both proteasome inhibitors bortezomib and carfilzomib. Within a multicentre phase I/II study, NOX-A12 was tested in combination with bortezomib-dexamethasone, underlining the feasibility of NOX-A12 as an active add-on agent to antagonize myeloma CAM-DR.
引用
- Waldschmidt JM, Simon A, Wider D, et al. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol. 2017. PMID: 28670693. doi:10.1111/bjh.14807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。